Like Viagra, Stendra, and Levitra, Cialis (the brand name of the active ingredient tadalafil) is highly effective as a ...

Cluster of differentiation 73 (CD73) converts adenosine 5′-monophosphate to immunosuppressive adenosine, and its inhibition was proposed as a new strategy for cancer treatment. We synthesized ...

Rates of Raynaud phenomenon medication initiation are low among patients with SSc in the United States, with less than one-third receiving consistent treatment.

At the well-controlled HbA1c of the participants, previous literature shows current diabetes treatments have similar HbA1c decreases, so the HbA1c mean difference of long half-life PDE5 inhibitors may ...

Arcutis Biotherapeutics Inc. (NASDAQ:ARQT) is one of the most promising stocks according to Wall Street analysts. On June 26, ...

The disease primarily affects middle-aged women and has a poor long-term prognosis despite therapeutic advances.

Raynaud phenomenon-related medications were classified as calcium-channel blockers (CCBs), renin-angiotensin system (RAS) inhibitors, phosphodiesterase-5 (PDE5) inhibitors, endothelin receptor ...

Celastrol has been identified as a reactive oxygen species (ROS) elevator that reduces cancer cell proliferation by inhibiting peroxiredoxin (PRDX) activity, albeit with poor selectivity. We describe ...

Methods: In the EDATE observational study, phosphodiesterase-type-5 (PDE5)-inhibitor pretreated or naïve ED patients who started or switched to TAD-OaD were prospectively followed for 6 months.

The use of PDE-5 inhibitors has proven very effective in alleviating the physical effects of reduced erectile function in many men.

Bone growth occurs through the proliferation of specialized cells of the cartilage tissue, known as chondrocytes, on either end of a bone. This process requires the synthesis of extracellular matrix ...

PDE3 inhibitors are already in clinical use for treating heart failure, thrombosis, asthma, and other conditions, but their potential in promoting bone outgrowth by enhancing CNP signaling ...